Travere Therapeutics Stock Performance
| TVTX Stock | USD 20.65 0.58 2.73% |
On a scale of 0 to 100, Travere Therapeutics holds a performance score of 4. The entity has a beta of 1.76, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Travere Therapeutics will likely underperform. Please check Travere Therapeutics' maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to make a quick decision on whether Travere Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Travere Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Travere Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.73) | Five Day Return (3.95) | Year To Date Return 8.86 | Ten Year Return 38.59 | All Time Return 1.3 K |
Last Split Factor 1:9 | Last Split Date 2011-11-08 |
1 | Disposition of 15000 shares by Sandra Calvin of Travere Therapeutics at 12.67 subject to Rule 16b-3 | 11/25/2024 |
2 | Acquisition by Sandra Calvin of 25000 shares of Travere Therapeutics at 8.93 subject to Rule 16b-3 | 11/29/2024 |
3 | Disposition of 2066 shares by Inrig Jula of Travere Therapeutics at 19.1 subject to Rule 16b-3 | 01/03/2025 |
4 | Travere Therapeutics Price Target Raised to 22.00 at HC Wainwright - MarketBeat | 01/15/2025 |
5 | Disposition of 925 shares by Sandra Calvin of Travere Therapeutics at 18.9408 subject to Rule 16b-3 | 01/22/2025 |
6 | Disposition of 16000 shares by Baynes Roy D. of Travere Therapeutics at 17.5 subject to Rule 16b-3 | 01/23/2025 |
7 | Disposition of 3348 shares by Sandra Calvin of Travere Therapeutics at 20.12 subject to Rule 16b-3 | 02/03/2025 |
8 | Disposition of 1066 shares by Inrig Jula of Travere Therapeutics at 20.11 subject to Rule 16b-3 | 02/04/2025 |
9 | Disposition of 10000 shares by Baynes Roy D. of Travere Therapeutics at 17.44 subject to Rule 16b-3 | 02/06/2025 |
10 | Disposition of 8000 shares by Inrig Jula of Travere Therapeutics subject to Rule 16b-3 | 02/10/2025 |
11 | Travere Therapeutics Inc Announces Inducement Equity Grants for New Employees | 02/12/2025 |
12 | Travere Therapeutics Inc Announces Upcoming Financial Results Release | 02/13/2025 |
13 | Travere Therapeutics Among The SmallCap Stocks Insiders Are Selling Recently | 02/14/2025 |
14 | Travere Therapeutics Inc Reports Q4 2024 Revenue of 73. ... | 02/20/2025 |
15 | Q4 2024 Travere Therapeutics Inc Earnings Call Transcript | 02/21/2025 |
16 | Citigroup Boosts Travere Therapeutics Price Target to 35.00 | 02/24/2025 |
| Begin Period Cash Flow | 58.2 M |
Travere |
Travere Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,881 in Travere Therapeutics on November 28, 2024 and sell it today you would earn a total of 184.00 from holding Travere Therapeutics or generate 9.78% return on investment over 90 days. Travere Therapeutics is currently generating 0.2243% in daily expected returns and assumes 3.6197% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Travere, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Travere Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Travere Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Travere Therapeutics, and traders can use it to determine the average amount a Travere Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.062
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TVTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.62 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Travere Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Travere Therapeutics by adding it to a well-diversified portfolio.
Travere Therapeutics Fundamentals Growth
Travere Stock prices reflect investors' perceptions of the future prospects and financial health of Travere Therapeutics, and Travere Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Travere Stock performance.
| Return On Equity | -2.47 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.38) % | ||||
| Operating Margin | (0.79) % | ||||
| Current Valuation | 1.86 B | ||||
| Shares Outstanding | 88.74 M | ||||
| Price To Book | 30.99 X | ||||
| Price To Sales | 7.86 X | ||||
| Revenue | 233.18 M | ||||
| Gross Profit | 7.93 M | ||||
| EBITDA | (320.63 M) | ||||
| Net Income | (321.55 M) | ||||
| Cash And Equivalents | 553.17 M | ||||
| Cash Per Share | 8.65 X | ||||
| Total Debt | 401.58 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 4.71 X | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (230.02 M) | ||||
| Earnings Per Share | (4.07) X | ||||
| Market Capitalization | 1.83 B | ||||
| Total Asset | 594.12 M | ||||
| Retained Earnings | (1.45 B) | ||||
| Working Capital | 215.95 M | ||||
About Travere Therapeutics Performance
Evaluating Travere Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Travere Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Travere Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 344.96 | 437.62 | |
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.82) | (0.77) | |
| Return On Assets | (0.54) | (0.57) | |
| Return On Equity | (5.44) | (5.17) |
Things to note about Travere Therapeutics performance evaluation
Checking the ongoing alerts about Travere Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Travere Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Travere Therapeutics had very high historical volatility over the last 90 days | |
| Travere Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 233.18 M. Net Loss for the year was (321.55 M) with profit before overhead, payroll, taxes, and interest of 7.93 M. | |
| Travere Therapeutics currently holds about 553.17 M in cash with (230.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Citigroup Boosts Travere Therapeutics Price Target to 35.00 |
- Analyzing Travere Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Travere Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Travere Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Travere Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Travere Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Travere Therapeutics' stock. These opinions can provide insight into Travere Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.